WO2017041228A1 - Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof - Google Patents

Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof Download PDF

Info

Publication number
WO2017041228A1
WO2017041228A1 PCT/CN2015/089162 CN2015089162W WO2017041228A1 WO 2017041228 A1 WO2017041228 A1 WO 2017041228A1 CN 2015089162 W CN2015089162 W CN 2015089162W WO 2017041228 A1 WO2017041228 A1 WO 2017041228A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
preparation
prepared
Prior art date
Application number
PCT/CN2015/089162
Other languages
French (fr)
Chinese (zh)
Inventor
朱国良
张斌
陈小华
李杰平
钱灵锋
徐立
杜小华
何大伟
Original Assignee
浙江九洲药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江九洲药业股份有限公司 filed Critical 浙江九洲药业股份有限公司
Priority to PCT/CN2015/089162 priority Critical patent/WO2017041228A1/en
Priority to CN202010282019.5A priority patent/CN111410607B/en
Priority to CN201610726487.0A priority patent/CN106496263B/en
Publication of WO2017041228A1 publication Critical patent/WO2017041228A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the field of pharmaceutical synthesis, in particular to a preparation method of a hexahydrofuranfuranol derivative, an intermediate thereof and a preparation method thereof.
  • a compound having the structure of the following formula Z is a chemical name of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol:
  • One of the derivatives of hexahydrofuranfuranol is an intermediate of the anti-AIDS drug darunavir.
  • the method for preparing (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol of the present invention starts from the selection of starting materials, and the research and development are different from the above-mentioned existing patent applications.
  • the starting material is used to prepare a key intermediate of darunavir.
  • the preparation method of the present invention provides another route suitable for industrialization for the preparation of the key intermediate of darunavir.
  • the present invention provides the following technical solutions:
  • the first aspect of the invention provides the following compound of formula B,
  • R 1 , R 2 are hydrogen, the same or different are carboxy protecting groups such as alkyl, substituted phenyl such as alkyl substituted phenyl, alkoxyalkyl substituted phenyl, nitroalkyl substituted Phenyl or silane group;
  • PG is hydrogen or a hydroxy protecting group such as an alkyl group, an alkylsilyl group, an aryl group or the like.
  • the alkyl group is a C 1 -C 8 alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl;
  • the alkyl-substituted phenyl group is a benzyl group, a benzyl group, a trityl group;
  • the alkoxyalkyl-substituted phenyl group is a p-methoxybenzyl group;
  • the nitroalkyl-substituted phenyl group is a p-nitrobenzyl group, etc., preferably, Methyl, isopropyl, tert-butyl, benzyl;
  • the alkyl silicon group is trimethylsilyl, triethylsilyl, tri-n-butylsilyl, tert-butyldimethylsilyl;
  • the aryl group is pheny
  • a second aspect of the invention provides the following compound of formula C,
  • R 2 has the same definition as defined in the compound of formula B above.
  • a third aspect of the invention provides the following compound of formula D,
  • the fourth aspect of the present invention provides a method for preparing a compound of the formula B and the formula B-1, wherein The compound of the formula B-1 is prepared by reacting a compound of the formula A1 with a compound of the formula A2, and the compound of the formula B is the same, and the compound of the formula A1 is adjusted to its racemate,
  • R 1 , R 2 , PG are the same as defined above, and X is a leaving group.
  • X may be a halogen atom, preferably an iodine atom, a bromine atom; a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, a p-toluenesulfonyloxy group, or a benzenesulfonyloxy group.
  • R 1 , R 2 and X are the same as defined above.
  • R 1 , R 2 and X are the same as defined above.
  • R 1 , R 2 and X are the same as defined above.
  • R 1 , R 2 and X are the same as defined above.
  • the compound of the formula B-1 wherein the protecting group is hydrogen can be prepared by deprotecting the protecting group to an alkyl group, a benzyl group or an alkylsilyl group.
  • the alkyl group is subjected to acid hydrolysis to a hydroxyl group, and the benzyl group and the diphenylmethyl group are deprotected to a hydroxyl group by palladium carbon, and the alkyl silicon group is deprotected to a hydroxyl group by an acid such as trifluoroacetic acid.
  • the reaction for preparing the compound of the formula B-1 is carried out in the presence of a base.
  • the base is an alkyl lithium or a compound of the following structure,
  • L 1, L 2 is alkyl, cycloalkyl, alkylsilyl, M being a metal atom such as lithium, potassium and sodium.
  • the base is lithium diisopropylamide, lithium cyclohexylamide, hexamethyl Lithium silicon nitride, sodium hexamethyldisilazide, potassium hexamethyldisilazide or n-butyllithium.
  • the base is lithium diisopropylamide.
  • the base is usually used in an amount of from 2.0 to 3.5 mol, preferably from 2.2 mol to 3.0 mol, per mol of the compound of the formula A1.
  • the reaction solvent is an ether solvent such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyltetrahydrofuran or the like.
  • the reaction temperature is -78 ° C to 70 ° C, preferably -78 ° C to 0 ° C.
  • the compound of the formula B-1 obtained by the reaction of the compound of the formula A1 with the compound of the formula A2 is mostly present in a compound of the following configuration
  • a person skilled in the art can purify the compound of the formula B-1 by column chromatography or the like.
  • the completion of the reaction may first pass through three processes of deprotection, post-cyclization, and hydrolysis, or may be hydrolysis first, then deprotection, re-cyclization, and It may be a process of first deprotecting, post-hydrolysis, and re-cyclization. That is, these three processes in any order.
  • the deprotecting reagent is acid or palladium carbon, and the cyclizing reagent may be an acid, wherein the acid is an inorganic acid or an organic acid; and the hydrolysis reagent is an inorganic base.
  • the inorganic acid is hydrochloric acid or sulfuric acid; the organic acid is trifluoroacetic acid, and the inorganic base is sodium hydroxide, sodium carbonate or the like.
  • the preparation of the compound of the formula C of the present invention can also be carried out by reacting the compound of the formula A1 with the compound of the formula A2, and then subjecting it to a one-pot reaction of deprotection, cyclization and hydrolysis in any order.
  • the fifth aspect of the present invention provides a method for preparing a compound of the formula C1, an organic amine salt, wherein the organic amine reagent may be an amine having an active hydrogen such as a primary amine on nitrogen, or an amine having no active hydrogen on the nitrogen such as a tertiary amine. Amines, etc.
  • the organic amine reagent may be dibenzylamine, benzylamine, dicyclohexylamine, cyclohexylamine, aniline, diethylamine, diisopropylamine, (S)-phenethylamine, diisopropylethylamine.
  • Triethylamine preferably dibenzylamine.
  • the organic amine is usually used in an amount of from 0.5 to 1.5 mol, preferably from 0.8 to 1.3 mol, per mol of the compound of the formula C1.
  • the solvent is an alcohol solvent, a ketone solvent, an ether solvent, or an ester solvent.
  • It is an alcohol solvent, an ether solvent or a ketone solvent.
  • the alcohol solvent is methanol, ethanol, 2-propanol, 1-propanol, tert-butanol;
  • the ketone solvent is methyl isobutyl ketone or acetone;
  • the ether solvent is methyl t-butyl Ether or diisopropyl ether;
  • the ester solvent is ethyl acetate.
  • the formation of the organic amine salt can be carried out by heating to a temperature of usually 20 ° C to 100 ° C, preferably 50 ° C to 80 ° C, followed by cooling to a temperature of usually -20 ° C to 40 ° C, preferably -10 ° C to 25 ° C.
  • the recrystallization solvent is the same as the above reaction solvent, and is preferably a ketone solvent such as acetone.
  • the compound of the formula C1 can be further obtained by a free step. However, it can also be used in the next reaction without being liberated.
  • the acid used in the free step is a mineral acid such as hydrochloric acid, sulfuric acid or phosphoric acid, preferably hydrochloric acid.
  • a process for the preparation of a compound of the formula D-1 which is prepared from the above-mentioned compound of the formula C1 and an organic amine salt.
  • the acid binding agent is a tertiary amine such as triethylamine or diisopropylethylamine, and may also be pyridine.
  • the solvent is an ether solvent such as tetrahydrofuran or a halogenated alkane solvent such as dichloromethane.
  • the reaction temperature is from 0 ° C to 50 ° C.
  • a catalyst may optionally be added to the reaction, and the catalyst is 4-dimethylaminopyridine.
  • a seventh aspect of the invention provides a process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol from a compound of formula D-1. It is prepared from the compound of the formula D-1 by reduction and cyclization in two steps.
  • the reducing agent is an aluminum reagent such as lithium aluminum hydride, diisobutylaluminum hydride or sodium dihydrobis(2-methoxyethoxy)aluminate (red aluminum), tri-tert-butoxy aluminum hydride lithium.
  • aluminum reagent such as lithium aluminum hydride, diisobutylaluminum hydride or sodium dihydrobis(2-methoxyethoxy)aluminate (red aluminum), tri-tert-butoxy aluminum hydride lithium.
  • the solvent for the reduction reaction is an ether solvent, a single solvent or a mixed solvent of a halogenated hydrocarbon or a hydrocarbon solvent.
  • the ether solvent is tetrahydrofuran; the halogenated hydrocarbon solvent is dichloromethane, chlorobenzene.
  • the cyclizing reagent is a mineral acid, an organic acid or an aqueous solution.
  • the inorganic acid is hydrochloric acid, sulfuric acid; the organic acid is methanesulfonic acid, p-toluenesulfonic acid.
  • the solvent for the cyclization reaction is an ether solvent and an alcohol solvent.
  • a more preferred embodiment is the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol by a one-pot reaction of the compound of formula C1 and the organic amine salt.
  • reaction solvent is preferably an ether solvent.
  • Another preferred embodiment is the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol by a one-pot reaction of a compound of formula C1.
  • reaction solvent is preferably an ether solvent.
  • the invention prepares the key intermediate of darunavir (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, starting from the compound of formula A1,
  • R 1 and R 2 are the same as defined above. This is different from the starting materials reported in the prior patent documents. The specific preparation method is also different from the prior patent documents, but the preparation method can industrially produce the key intermediate of darunavir.
  • control temperature does not exceed -60 ° C, drop, maintain internal temperature Stir for 30 min, slowly warm to -20 ° C, use for half an hour, then cool to -60 ° C ⁇ -70 ° C, add 2-iodoethyl tert-butyl ether (27.4 g, 2.0 eq) dropwise, stir and keep stirring for half an hour After that, the temperature was raised to -20 ° C and stirred overnight.
  • the reaction system was added with 90 ml of water and 40 ml of ethyl acetate, and the mixture was stirred for 5 min, and the mixture was separated, and the aqueous layer was extracted with ethyl acetate (40 ml ⁇ 3). Part of the column was separated and identified as the target compound in a yield of 80%.
  • Product spectrum data is as follows:
  • control temperature does not exceed -60 ° C, drip, maintain internal temperature for 30min, slowly warm to -20 ° C, use half an hour, then cool to -60 ° C ⁇ -70 ° C, add 2-iodoethyl tert-Butyl ether (9.58 g, 2.0 eq) was added and stirred for half an hour, then warmed to -20 ° C and stirred overnight.
  • the reaction system was added with 90 ml of water and 40 ml of ethyl acetate, and the mixture was stirred for 5 min, and the mixture was separated, and the aqueous layer was extracted with ethyl acetate (40 ml ⁇ 3). Partial separation of the column, determined as the target Compound, yield 60%.
  • Product spectrum data is as follows:
  • the compound of the formula B-1 whose protecting group is a trimethylsilyl group can be prepared according to the embodiment 1 or 2.
  • a compound of formula B-1 wherein the protecting group is benzyl can be prepared as in Example 1 or 2.
  • the compound of formula B-1 having a protecting group of hydrogen can be prepared by deprotection, and the product spectrum data is as follows:
  • Example 8 Preparation of a compound of formula C1 ⁇ dibenzylamine salt A one-pot reaction of (3R,3aS,6aR)-hexahydrofuro[2,3-b]-3-ol

Abstract

The present invention relates to the field of pharmaceutical synthesis, in particular to a method for preparing a hexahydrofurofuranol derivative, an intermediate thereof and a preparation method thereof. The preparation method uses a compound of formula A1 as an initial material, wherein R1 and R2 are the same or different alkyls, which differs from the initial material reported by the present patent documents, and the specific preparation method is different from that of the prior art patent documents; however, the preparation method can achieve the industrial production of a Darunavir key intermediate, (3R,3aS,6aR)-hexahydrofuro[2,3-b]-3-alcohol.

Description

六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法Preparation method of hexahydrofuranfuranol derivative, intermediate thereof and preparation method thereof 技术领域Technical field
本发明涉及医药合成领域,具体涉及六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法。The invention relates to the field of pharmaceutical synthesis, in particular to a preparation method of a hexahydrofuranfuranol derivative, an intermediate thereof and a preparation method thereof.
背景技术Background technique
具有下列式Z结构的化合物为化学名称为(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇:A compound having the structure of the following formula Z is a chemical name of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol:
Figure PCTCN2015089162-appb-000001
Figure PCTCN2015089162-appb-000001
属于六氢呋喃并呋喃醇衍生物的一种,是抗艾滋病药物达芦那韦的中间体。One of the derivatives of hexahydrofuranfuranol is an intermediate of the anti-AIDS drug darunavir.
泰博特克药品有限公司的中国专利申请号为200580010400.X提供了上述(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的制备方法,其中起始原料为如下的式(3)化合物,The preparation method of the above (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol is provided in Chinese Patent Application No. 200580010400.X of Taibotek Pharmaceutical Co., Ltd., wherein the starting material is a compound of the formula (3) below,
Figure PCTCN2015089162-appb-000002
Figure PCTCN2015089162-appb-000002
日本住友化学株式会社的中国专利申请号为200380109926.4提供了上述(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的制备方法,其中起始原料为如下的式XⅢ化合物,The preparation method of the above (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol is provided in the Japanese Patent Application No. 200380109926.4 of Sumitomo Chemical Co., Ltd., wherein the starting material is as follows XIII compound,
Figure PCTCN2015089162-appb-000003
Figure PCTCN2015089162-appb-000003
考虑到(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇是制备达芦那韦药 物的关键中间体,有必要开发出更多的该关键中间体的制备方法。这就要求从不同的起始原料着手研发。Considering (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol is a preparation of darunavir For key intermediates, it is necessary to develop more preparation methods for this key intermediate. This requires research and development from different starting materials.
发明内容Summary of the invention
本发明的制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的方法从起始原料的选择上着手,研究开发出了不同于上述已有专利申请中的起始原料制备达芦那韦关键中间体的制备方法。本发明的制备方法为该达芦那韦关键中间体的制备提供了另一条适合产业化的路线。The method for preparing (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol of the present invention starts from the selection of starting materials, and the research and development are different from the above-mentioned existing patent applications. The starting material is used to prepare a key intermediate of darunavir. The preparation method of the present invention provides another route suitable for industrialization for the preparation of the key intermediate of darunavir.
为实现本发明的技术目的,本发明提供了如下的技术方案:To achieve the technical object of the present invention, the present invention provides the following technical solutions:
本发明第一方面提供了如下的式B化合物,The first aspect of the invention provides the following compound of formula B,
Figure PCTCN2015089162-appb-000004
Figure PCTCN2015089162-appb-000004
特别地,如下的式B-1化合物,In particular, the following compound of formula B-1,
Figure PCTCN2015089162-appb-000005
Figure PCTCN2015089162-appb-000005
其中,R1,R2为氢,相同或不同的为羧基保护基,如烷基,取代苯基如烷基取代的苯基,烷氧基烷基取代的苯基,硝基烷基取代的苯基或硅烷基;PG为氢或羟基保护基,如烷基,烷基硅基,芳基等。Wherein R 1 , R 2 are hydrogen, the same or different are carboxy protecting groups such as alkyl, substituted phenyl such as alkyl substituted phenyl, alkoxyalkyl substituted phenyl, nitroalkyl substituted Phenyl or silane group; PG is hydrogen or a hydroxy protecting group such as an alkyl group, an alkylsilyl group, an aryl group or the like.
所述烷基为C1-C8的烷基,如甲基,乙基,正丙基,异丙基,正丁基,叔丁基;所述烷基取代的苯基为苄基,二苯甲基,三苯甲基;所述烷 氧基烷基取代的苯基为对甲氧基苄基;所述硝基烷基取代的苯基为对硝基苄基等,优选地,为甲基、异丙基,叔丁基,苄基;所述烷基硅基为三甲基硅基,三乙基硅基,三正丁基硅基,叔丁基二甲基硅基;所述芳基为苯基,呋喃基,噻吩基,吲哚基。The alkyl group is a C 1 -C 8 alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; the alkyl-substituted phenyl group is a benzyl group, a benzyl group, a trityl group; the alkoxyalkyl-substituted phenyl group is a p-methoxybenzyl group; the nitroalkyl-substituted phenyl group is a p-nitrobenzyl group, etc., preferably, Methyl, isopropyl, tert-butyl, benzyl; the alkyl silicon group is trimethylsilyl, triethylsilyl, tri-n-butylsilyl, tert-butyldimethylsilyl; The aryl group is phenyl, furyl, thienyl, fluorenyl.
本发明第二方面提供了如下的式C化合物,A second aspect of the invention provides the following compound of formula C,
Figure PCTCN2015089162-appb-000006
Figure PCTCN2015089162-appb-000006
特别地,如下的式C1化合物,In particular, the following compound of formula C1,
Figure PCTCN2015089162-appb-000007
Figure PCTCN2015089162-appb-000007
其中,R2的定义与上面式B化合物中的定义相同。Wherein R 2 has the same definition as defined in the compound of formula B above.
本发明第三方面提供了如下的式D化合物,A third aspect of the invention provides the following compound of formula D,
Figure PCTCN2015089162-appb-000008
Figure PCTCN2015089162-appb-000008
特别地,如下的式D-1化合物,In particular, the following compound of formula D-1,
Figure PCTCN2015089162-appb-000009
Figure PCTCN2015089162-appb-000009
本发明第四方面提供了式B及式B-1化合物的制备方法,其中, 式B-1化合物由式A1化合物与式A2化合物反应制备得到,式B化合物与之相同,将式A1化合物调整为其外消旋物即可,The fourth aspect of the present invention provides a method for preparing a compound of the formula B and the formula B-1, wherein The compound of the formula B-1 is prepared by reacting a compound of the formula A1 with a compound of the formula A2, and the compound of the formula B is the same, and the compound of the formula A1 is adjusted to its racemate,
Figure PCTCN2015089162-appb-000010
Figure PCTCN2015089162-appb-000010
其中,R1,R2,PG与上述定义相同,所述X为离去基团。Wherein R 1 , R 2 , PG are the same as defined above, and X is a leaving group.
X可以为卤素原子,优选地为碘原子,溴原子;甲磺酰氧基、三氟甲磺酰氧基、对甲苯磺酰氧基、苯磺酰氧基。X may be a halogen atom, preferably an iodine atom, a bromine atom; a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, a p-toluenesulfonyloxy group, or a benzenesulfonyloxy group.
具体地,制备保护基PG为叔丁基的式B-1化合物,Specifically, a compound of the formula B-1 wherein the protecting group PG is a tert-butyl group is prepared,
Figure PCTCN2015089162-appb-000011
Figure PCTCN2015089162-appb-000011
其中,R1,R2,X与上述定义相同。Wherein R 1 , R 2 and X are the same as defined above.
具体地,制备保护基PG为三甲基硅烷基的式B-1化合物,Specifically, a compound of the formula B-1 wherein the protecting group PG is a trimethylsilyl group is prepared,
Figure PCTCN2015089162-appb-000012
Figure PCTCN2015089162-appb-000012
其中,R1,R2,X与上述定义相同。Wherein R 1 , R 2 and X are the same as defined above.
具体地,制备保护基PG为苄基的式B-1化合物, Specifically, a compound of the formula B-1 wherein the protecting group PG is a benzyl group is prepared,
Figure PCTCN2015089162-appb-000013
Figure PCTCN2015089162-appb-000013
其中,R1,R2,X与上述定义相同。Wherein R 1 , R 2 and X are the same as defined above.
具体地,制备保护基PG为二苯甲基的式B-1化合物,Specifically, a compound of the formula B-1 wherein the protecting group PG is a diphenylmethyl group is prepared,
Figure PCTCN2015089162-appb-000014
Figure PCTCN2015089162-appb-000014
其中,R1,R2,X与上述定义相同。Wherein R 1 , R 2 and X are the same as defined above.
其中,保护基为氢的式B-1化合物可以由保护基为烷基,苄基或烷基硅基经脱保护制备得到。如使烷基经酸水解为羟基,使苄基,二苯甲基经钯炭脱保护为羟基,使烷基硅基经酸如三氟乙酸脱保护为羟基。所述制备式B-1化合物的反应在碱存在的条件下进行。所述碱为烷基锂或如下结构的化合物,Among them, the compound of the formula B-1 wherein the protecting group is hydrogen can be prepared by deprotecting the protecting group to an alkyl group, a benzyl group or an alkylsilyl group. For example, the alkyl group is subjected to acid hydrolysis to a hydroxyl group, and the benzyl group and the diphenylmethyl group are deprotected to a hydroxyl group by palladium carbon, and the alkyl silicon group is deprotected to a hydroxyl group by an acid such as trifluoroacetic acid. The reaction for preparing the compound of the formula B-1 is carried out in the presence of a base. The base is an alkyl lithium or a compound of the following structure,
Figure PCTCN2015089162-appb-000015
Figure PCTCN2015089162-appb-000015
其中,L1,L2为烷基,环烷基,烷基硅基,M为金属原子如锂,钾,钠等。Wherein, L 1, L 2 is alkyl, cycloalkyl, alkylsilyl, M being a metal atom such as lithium, potassium and sodium.
具体地,所述碱为二异丙基氨基化锂、环己基氨基化锂、六甲基 二硅氮化锂、六甲基二硅氮化钠、六甲基二硅氮化钾或正丁基锂。Specifically, the base is lithium diisopropylamide, lithium cyclohexylamide, hexamethyl Lithium silicon nitride, sodium hexamethyldisilazide, potassium hexamethyldisilazide or n-butyllithium.
优选地,所述碱为二异丙基氨基化锂。Preferably, the base is lithium diisopropylamide.
相对于1mol的式A1化合物,碱的使用量通常为2.0~3.5mol,优选地,为2.2mol~3.0mol。The base is usually used in an amount of from 2.0 to 3.5 mol, preferably from 2.2 mol to 3.0 mol, per mol of the compound of the formula A1.
所述反应溶剂为醚类溶剂如乙醚,异丙醚,甲基叔丁基醚,四氢呋喃,甲基四氢呋喃等。The reaction solvent is an ether solvent such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyltetrahydrofuran or the like.
所述反应温度为-78℃-70℃,优选为-78℃-0℃。The reaction temperature is -78 ° C to 70 ° C, preferably -78 ° C to 0 ° C.
其中,式A1化合物与式A2化合物的反应制备得到的式B-1化合物大部分地以如下构型的化合物存在,Wherein, the compound of the formula B-1 obtained by the reaction of the compound of the formula A1 with the compound of the formula A2 is mostly present in a compound of the following configuration,
Figure PCTCN2015089162-appb-000016
Figure PCTCN2015089162-appb-000016
少部分地以其非对映异构体的形式存在,Less in part in the form of its diastereomers,
Figure PCTCN2015089162-appb-000017
Figure PCTCN2015089162-appb-000017
本领域技术人员可以在此通过柱层析等方法提纯得到式B-1化合物,A person skilled in the art can purify the compound of the formula B-1 by column chromatography or the like.
Figure PCTCN2015089162-appb-000018
Figure PCTCN2015089162-appb-000018
但较优选地是,不提纯直接用于下述反应,制备式C化合物, More preferably, however, it is directly used in the following reaction without purification to prepare a compound of formula C,
Figure PCTCN2015089162-appb-000019
Figure PCTCN2015089162-appb-000019
其中,由于上述式B-1化合物大部分以如下构型存在,Wherein, since most of the compounds of the above formula B-1 exist in the following configuration,
Figure PCTCN2015089162-appb-000020
Figure PCTCN2015089162-appb-000020
那经过反应后,生成的式C化合物也是以如下构型存在,After the reaction, the resulting compound of formula C also exists in the following configuration.
Figure PCTCN2015089162-appb-000021
Figure PCTCN2015089162-appb-000021
少部分以如下构型存在,A small part exists in the following configuration,
Figure PCTCN2015089162-appb-000022
Figure PCTCN2015089162-appb-000022
其中,当R2为氢时,所述反应的完成可以先通过脱保护基,后环合,再水解这三个过程,也可以是先水解,后脱保护基,再环合的过程,还可以是先脱保护基,后水解,再环合的过程。即任意顺序地这三个过程。 Wherein, when R 2 is hydrogen, the completion of the reaction may first pass through three processes of deprotection, post-cyclization, and hydrolysis, or may be hydrolysis first, then deprotection, re-cyclization, and It may be a process of first deprotecting, post-hydrolysis, and re-cyclization. That is, these three processes in any order.
Figure PCTCN2015089162-appb-000023
Figure PCTCN2015089162-appb-000023
所述脱保护试剂为酸或钯炭,所述环合试剂可以为酸,其中酸为无机酸或有机酸;所述水解试剂为无机碱。The deprotecting reagent is acid or palladium carbon, and the cyclizing reagent may be an acid, wherein the acid is an inorganic acid or an organic acid; and the hydrolysis reagent is an inorganic base.
所述无机酸为盐酸、硫酸;所述有机酸为三氟乙酸,所述无机碱为氢氧化钠,碳酸钠等。The inorganic acid is hydrochloric acid or sulfuric acid; the organic acid is trifluoroacetic acid, and the inorganic base is sodium hydroxide, sodium carbonate or the like.
本发明式C化合物的制备还可以由式A1化合物与式A2化合物反应后,经任意顺序地脱保护,环合和水解的一锅反应制备得到,The preparation of the compound of the formula C of the present invention can also be carried out by reacting the compound of the formula A1 with the compound of the formula A2, and then subjecting it to a one-pot reaction of deprotection, cyclization and hydrolysis in any order.
Figure PCTCN2015089162-appb-000024
Figure PCTCN2015089162-appb-000024
本发明第五方面提供了式C1化合物·有机胺盐的制备方法,其中,所述有机胺试剂可以为氮上有活性氢的胺如伯胺,也可以为氮上没有活性氢的胺如叔胺等。The fifth aspect of the present invention provides a method for preparing a compound of the formula C1, an organic amine salt, wherein the organic amine reagent may be an amine having an active hydrogen such as a primary amine on nitrogen, or an amine having no active hydrogen on the nitrogen such as a tertiary amine. Amines, etc.
具体地,所述有机胺试剂可以为二苄胺、苄胺、二环己胺、环己胺、苯胺、二乙胺、二异丙胺、(S)-苯乙胺,二异丙基乙胺,三乙胺,优选二苄胺。相对于1mol式C1化合物,有机胺的使用量通常为0.5-1.5mol,优选0.8-1.3mol。Specifically, the organic amine reagent may be dibenzylamine, benzylamine, dicyclohexylamine, cyclohexylamine, aniline, diethylamine, diisopropylamine, (S)-phenethylamine, diisopropylethylamine. Triethylamine, preferably dibenzylamine. The organic amine is usually used in an amount of from 0.5 to 1.5 mol, preferably from 0.8 to 1.3 mol, per mol of the compound of the formula C1.
Figure PCTCN2015089162-appb-000025
Figure PCTCN2015089162-appb-000025
所述溶剂为醇类溶剂,酮类溶剂,醚类溶剂,酯类溶剂。优选地, 为醇类溶剂,醚类溶剂或酮类溶剂。The solvent is an alcohol solvent, a ketone solvent, an ether solvent, or an ester solvent. Preferably, It is an alcohol solvent, an ether solvent or a ketone solvent.
所述醇类溶剂为甲醇、乙醇、2-丙醇、1-丙醇、叔丁醇;所述酮类溶剂为甲基异丁基酮或丙酮;所述醚类溶剂为甲基叔丁基醚或二异丙醚;所述酯类溶剂为乙酸乙酯。The alcohol solvent is methanol, ethanol, 2-propanol, 1-propanol, tert-butanol; the ketone solvent is methyl isobutyl ketone or acetone; and the ether solvent is methyl t-butyl Ether or diisopropyl ether; the ester solvent is ethyl acetate.
有机胺盐的生成可以通过加热至通常20℃-100℃、优选50℃-80℃后,冷却至通常-20℃-40℃、优选-10℃-25℃来进行。The formation of the organic amine salt can be carried out by heating to a temperature of usually 20 ° C to 100 ° C, preferably 50 ° C to 80 ° C, followed by cooling to a temperature of usually -20 ° C to 40 ° C, preferably -10 ° C to 25 ° C.
一般地,所述的重结晶溶剂与上述反应溶剂一致,优选地,为酮类溶剂,如丙酮。Generally, the recrystallization solvent is the same as the above reaction solvent, and is preferably a ketone solvent such as acetone.
有机胺盐生成后,可以进一步通过游离的步骤获得式C1化合物。但也可以不游离,直接用于下一步反应。After the formation of the organic amine salt, the compound of the formula C1 can be further obtained by a free step. However, it can also be used in the next reaction without being liberated.
所述游离步骤使用的酸为无机酸,如盐酸、硫酸或磷酸,优选盐酸。The acid used in the free step is a mineral acid such as hydrochloric acid, sulfuric acid or phosphoric acid, preferably hydrochloric acid.
本发明第六方面提供了式D-1化合物的制备方法,由上述的式C1化合物·有机胺盐制备得到,According to a sixth aspect of the present invention, there is provided a process for the preparation of a compound of the formula D-1, which is prepared from the above-mentioned compound of the formula C1 and an organic amine salt.
Figure PCTCN2015089162-appb-000026
Figure PCTCN2015089162-appb-000026
当然,也可以经游离获得式C1化合物后,再制备式D化合物。Of course, it is also possible to prepare a compound of the formula D after freely obtaining a compound of the formula C1.
Figure PCTCN2015089162-appb-000027
Figure PCTCN2015089162-appb-000027
其中,缚酸剂为叔胺如三乙胺或二异丙基乙胺,还可以为吡啶。Wherein, the acid binding agent is a tertiary amine such as triethylamine or diisopropylethylamine, and may also be pyridine.
其中,所述溶剂为醚类溶剂如四氢呋喃或卤代烷类溶剂如二氯甲烷。 Wherein the solvent is an ether solvent such as tetrahydrofuran or a halogenated alkane solvent such as dichloromethane.
所述反应温度为0℃-50℃。The reaction temperature is from 0 ° C to 50 ° C.
反应中可选择性加入催化剂,所述催化剂为4-二甲氨基吡啶。A catalyst may optionally be added to the reaction, and the catalyst is 4-dimethylaminopyridine.
本发明第七方面提供了式D-1化合物制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的方法。由式D-1化合物经还原和环合两步制备得到。A seventh aspect of the invention provides a process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol from a compound of formula D-1. It is prepared from the compound of the formula D-1 by reduction and cyclization in two steps.
Figure PCTCN2015089162-appb-000028
Figure PCTCN2015089162-appb-000028
所述还原试剂为铝类试剂,如四氢铝锂,二异丁基氢化铝或二氢双(2-甲氧基乙氧基)铝酸钠(红铝),三叔丁氧基氢化铝锂。The reducing agent is an aluminum reagent such as lithium aluminum hydride, diisobutylaluminum hydride or sodium dihydrobis(2-methoxyethoxy)aluminate (red aluminum), tri-tert-butoxy aluminum hydride lithium.
所述还原反应的溶剂为醚类溶剂,卤代烃类或烃类溶剂的单一溶剂或混合溶剂。The solvent for the reduction reaction is an ether solvent, a single solvent or a mixed solvent of a halogenated hydrocarbon or a hydrocarbon solvent.
所述醚类溶剂为四氢呋喃;所述卤代烃类溶剂为二氯甲烷,氯苯。The ether solvent is tetrahydrofuran; the halogenated hydrocarbon solvent is dichloromethane, chlorobenzene.
所述环合试剂为无机酸,有机酸或水溶液。所述无机酸为盐酸,硫酸;所述有机酸为甲磺酸,对甲苯磺酸。The cyclizing reagent is a mineral acid, an organic acid or an aqueous solution. The inorganic acid is hydrochloric acid, sulfuric acid; the organic acid is methanesulfonic acid, p-toluenesulfonic acid.
所述环合反应的溶剂为醚类溶剂,醇类溶剂。The solvent for the cyclization reaction is an ether solvent and an alcohol solvent.
较优选的一种实施方式为,式C1化合物·有机胺盐经一锅反应制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇,A more preferred embodiment is the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol by a one-pot reaction of the compound of formula C1 and the organic amine salt.
Figure PCTCN2015089162-appb-000029
Figure PCTCN2015089162-appb-000029
其中,所述反应溶剂优选地为醚类溶剂。 Among them, the reaction solvent is preferably an ether solvent.
另一种较较优选的一种实施方式为,式C1化合物经一锅反应制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇,Another preferred embodiment is the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol by a one-pot reaction of a compound of formula C1.
Figure PCTCN2015089162-appb-000030
Figure PCTCN2015089162-appb-000030
其中,所述反应溶剂优选地为醚类溶剂。Among them, the reaction solvent is preferably an ether solvent.
本发明制备达芦那韦关键中间体(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的方法,以式A1化合物为起始原料,The invention prepares the key intermediate of darunavir (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, starting from the compound of formula A1,
Figure PCTCN2015089162-appb-000031
Figure PCTCN2015089162-appb-000031
其中,R1,R2与上述定义相同。这与现有专利文献中报导的起始原料不同,具体的制备方法也与现有专利文献不同,但该制备方法可产业化的生产达芦那韦该关键中间体。Wherein R 1 and R 2 are the same as defined above. This is different from the starting materials reported in the prior patent documents. The specific preparation method is also different from the prior patent documents, but the preparation method can industrially produce the key intermediate of darunavir.
具体实施方式detailed description
实施例1:(3R)-二异丙基-2-(2-(叔丁氧基)-乙基)-3-羟基的制备Example 1: Preparation of (3R)-diisopropyl-2-(2-(tert-butoxy)-ethyl)-3-hydroxyl
Figure PCTCN2015089162-appb-000032
Figure PCTCN2015089162-appb-000032
在一250ml配有磁力搅拌子,温度计的四口瓶中,氮气保护下,加入63ml LDA(2.1eq)和30ml THF,冷却至-60℃~-70℃,滴加苹果酸异丙酯(13.1g,60mmol),控制温度不超过-60℃,滴毕,维持内温 搅拌30min,缓慢升温至-20℃,用时半小时,再降温至-60℃~-70℃,滴加2-碘乙基叔丁基醚(27.4g,2.0eq),滴毕保温搅拌半小时后升温至-20℃搅拌过夜。反应体系加入90ml水和40ml乙酸乙酯,搅拌5min,静置分层,水相用(40ml×3)乙酸乙酯提取,合并有机层,硫酸镁干燥,过滤,浓缩得到28.54g油状物,取部分过柱分离,确定为目标化合物,收率80%。产品谱图数据如下:In a 250 ml four-necked flask equipped with a magnetic stirrer and a thermometer, under nitrogen protection, add 63 ml of LDA (2.1 eq) and 30 ml of THF, cool to -60 ° C to -70 ° C, and add isopropyl malate (13.1). g, 60mmol), control temperature does not exceed -60 ° C, drop, maintain internal temperature Stir for 30 min, slowly warm to -20 ° C, use for half an hour, then cool to -60 ° C ~ -70 ° C, add 2-iodoethyl tert-butyl ether (27.4 g, 2.0 eq) dropwise, stir and keep stirring for half an hour After that, the temperature was raised to -20 ° C and stirred overnight. The reaction system was added with 90 ml of water and 40 ml of ethyl acetate, and the mixture was stirred for 5 min, and the mixture was separated, and the aqueous layer was extracted with ethyl acetate (40 ml × 3). Part of the column was separated and identified as the target compound in a yield of 80%. Product spectrum data is as follows:
1H NMR(400.2MHz,CDCl3)δ5.10(1H,m),5.01(1H,m),4.31(1H,m),3.54(1H,d,J=7.2Hz),3.46(2H,m),3.06(1H,m),2.13(1H,m),1.86(1H,m),1.29(6H,d,J=2.8Hz),1.27(6H,d,J=2.8Hz),1.18(9H,s); 1 H NMR (400.2MHz, CDCl 3 ) δ5.10 (1H, m), 5.01 (1H, m), 4.31 (1H, m), 3.54 (1H, d, J = 7.2Hz), 3.46 (2H, m ), 3.06 (1H, m), 2.13 (1H, m), 1.86 (1H, m), 1.29 (6H, d, J = 2.8 Hz), 1.27 (6H, d, J = 2.8 Hz), 1.18 (9H) , s);
13C NMR(100.6MHz,CDCl3)δ172.8(d,J=8.8Hz),171.45(d,J=36.8Hz),72.83(d,J=5.9Hz),71.18(d,J=37.3Hz),69.48(t,J=8.2Hz),68.1(d,J=8.2Hz),58.88(s),45.67ppm(s),28.59(s),27.34ppm(s),21.58ppm(s); 13 C NMR (100.6 MHz, CDCl 3 ) δ 172.8 (d, J = 8.8 Hz), 171.45 (d, J = 36.8 Hz), 72.83 (d, J = 5.9 Hz), 71.18 (d, J = 37.3 Hz) ), 69.48 (t, J = 8.2 Hz), 68.1 (d, J = 8.2 Hz), 58.88 (s), 45.67 ppm (s), 28.59 (s), 27.34 ppm (s), 21.58 ppm (s);
质谱(ESI方法)C16H30O6(M)+,计算值318.20.测量值319.2Mass spectrometry (ESI method) C 16 H 30 O 6 (M) + calc.
实施例2:(3R)-二乙基-2-(2-(叔丁氧基)-乙基)-3-羟基的制备Example 2: Preparation of (3R)-diethyl-2-(2-(tert-butoxy)-ethyl)-3-hydroxyl
Figure PCTCN2015089162-appb-000033
Figure PCTCN2015089162-appb-000033
在一250ml配有磁力搅拌子,温度计的四口瓶中,氮气保护下,加入42ml LDA(2.1eq)和20ml THF,冷却至-60℃~-70℃,滴加苹果酸乙酯(7.5g,40mmol),控制温度不超过-60℃,滴毕,维持内温搅拌30min,缓慢升温至-20℃,用时半小时,再降温至-60℃~-70℃,滴加2-碘乙基叔丁基醚(9.58g,2.0eq),滴毕保温搅拌半小时后升温至-20℃搅拌过夜。反应体系加入90ml水和40ml乙酸乙酯,搅拌5min,静置分层,水相用(40ml×3)乙酸乙酯提取,合并有机层,硫酸镁干燥,过滤,浓缩得到7.49g油状物,取部分过柱分离,确定为目标 化合物,收率60%。产品谱图数据如下:In a 250 ml four-necked flask equipped with a magnetic stirrer and a thermometer, add 42 ml of LDA (2.1 eq) and 20 ml of THF under nitrogen, cool to -60 ° C to -70 ° C, and add ethyl malate (7.5 g). , 40mmol), control temperature does not exceed -60 ° C, drip, maintain internal temperature for 30min, slowly warm to -20 ° C, use half an hour, then cool to -60 ° C ~ -70 ° C, add 2-iodoethyl tert-Butyl ether (9.58 g, 2.0 eq) was added and stirred for half an hour, then warmed to -20 ° C and stirred overnight. The reaction system was added with 90 ml of water and 40 ml of ethyl acetate, and the mixture was stirred for 5 min, and the mixture was separated, and the aqueous layer was extracted with ethyl acetate (40 ml × 3). Partial separation of the column, determined as the target Compound, yield 60%. Product spectrum data is as follows:
1H NMR(400.2MHz,CDCl3)δ4.30(1H,m),4.20(2H,m),4.11(2H,m),3.52(1H,m),3.49(2H,m),3.10(1H,m),2.12(1H,m),1.88(1H,m),1.31(6H,d,J=2.8Hz),1.27(6H,d,J=2.8Hz),1.15(9H,s)。 1 H NMR (400.2MHz, CDCl 3 ) δ4.30 (1H, m), 4.20 (2H, m), 4.11 (2H, m), 3.52 (1H, m), 3.49 (2H, m), 3.10 (1H m), 2.12 (1H, m), 1.88 (1H, m), 1.31 (6H, d, J = 2.8 Hz), 1.27 (6H, d, J = 2.8 Hz), 1.15 (9H, s).
实施例3:(3R)-二异丙基甲基-2-(2-(三甲基硅氧基)-乙基)-3-羟基的制备Example 3: Preparation of (3R)-diisopropylmethyl-2-(2-(trimethylsiloxy)-ethyl)-3-hydroxyl
Figure PCTCN2015089162-appb-000034
Figure PCTCN2015089162-appb-000034
保护基为三甲基硅基的式B-1化合物可以按照实施例1或2制备。The compound of the formula B-1 whose protecting group is a trimethylsilyl group can be prepared according to the embodiment 1 or 2.
实施例4:Example 4:
Figure PCTCN2015089162-appb-000035
Figure PCTCN2015089162-appb-000035
保护基为苄基的的式B-1化合物可以按照实施例1或2制备。A compound of formula B-1 wherein the protecting group is benzyl can be prepared as in Example 1 or 2.
实施例5:Example 5:
Figure PCTCN2015089162-appb-000036
Figure PCTCN2015089162-appb-000036
保护基为氢的式B-1化合物可以经脱保护制备,产品谱图数据如下:The compound of formula B-1 having a protecting group of hydrogen can be prepared by deprotection, and the product spectrum data is as follows:
1H NMR(400.2MHz,CDCl3)δ5.14(1H,m),5.04(1H,m),4.53(2H,m),4.28(1H,s),3.22(1H,m),3.02(1H,m),2.60(1H,m),2.35(1H,m), 1.29(6H,m),1.25(6H,m); 1 H NMR (400.2MHz, CDCl 3 ) δ5.14 (1H, m), 5.04 (1H, m), 4.53 (2H, m), 4.28 (1H, s), 3.22 (1H, m), 3.02 (1H , m), 2.60 (1H, m), 2.35 (1H, m), 1.29 (6H, m), 1.25 (6H, m);
质谱(ESI方法)C12H22O6(M)+,计算值262.29.测量值263.2。Mass spectrum (ESI method) C 12 H 22 O 6 ( M) +, calcd 262.29. 263.2 measurements.
实施例6:式C化合物的制备Example 6: Preparation of a compound of formula C
在一50ml的两口瓶中加入300mg(3R)-二异丙基-2-(2-(叔丁氧基)-乙基)-3-羟基和1ml三氟乙酸,冷却至-10℃~-5℃搅拌过夜,低温蒸掉三氟乙酸,加入氢氧化钠水溶液和四氢呋喃于室温下搅拌6小时,后稀盐酸调pH=2,乙酸乙酯萃取,蒸干溶剂,加入甲苯,常压蒸干,此操作重复2次,得到127mg白色固体,收率为80%,核磁鉴定为目标化合物。产品谱图数据如下:Add 300 mg of (3R)-diisopropyl-2-(2-(tert-butoxy)-ethyl)-3-hydroxyl and 1 ml of trifluoroacetic acid to a 50 ml two-necked flask and cool to -10 °C~- Stir at 5 ° C overnight, dilute the trifluoroacetic acid at low temperature, add sodium hydroxide aqueous solution and tetrahydrofuran, stir at room temperature for 6 hours, adjust pH to 2 with dilute hydrochloric acid, extract with ethyl acetate, evaporate the solvent, add toluene, and dry at atmospheric pressure. This operation was repeated twice to obtain 127 mg of a white solid in a yield of 80%. Product spectrum data is as follows:
1H NMR(400.2MHz,DMSO-d6)δ4.25(3H,m),3.13(1H,m),2.33(1H,m),2.13(1H,m)。 1 H NMR (400.2 MHz, DMSO-d 6 ) δ 4.25 (3H, m), 3.13 (1H, m), 2.33 (1H, m), 2.13 (1H, m).
质谱(ESI方法)C6H8O5(M)-,计算值160.1测量值159.1。Mass spectrum (ESI method) C 6 H 8 O 5 ( M) -, calcd 160.1 159.1 measurements.
实施例7:式C1化合物·二苄胺盐的制备Example 7: Preparation of Compound C1 Dibenzylamine Salt of Formula C1
于一100ml的三口瓶中加入3.2g化合物C和30ml甲基叔丁基醚,滴加3.96g二苄胺,用时约30min,滴毕升温至50℃~55℃,保温3小时,慢慢降温至20℃,用时2小时,再保温3~10小时,过滤,得到白色固体6.0g,收率85%。Add 3.2g of compound C and 30ml of methyl tert-butyl ether to a 100ml three-necked flask, add 3.96g of dibenzylamine dropwise, use about 30min, drip to 50 °C ~ 55 °C, keep warm for 3 hours, slowly cool down It was kept at 20 ° C for 2 hours, and then kept for 3 to 10 hours, and filtered to obtain 6.0 g of a white solid. The yield was 85%.
实施例8:式C1化合物·二苄胺盐制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的一锅反应Example 8: Preparation of a compound of formula C1·dibenzylamine salt A one-pot reaction of (3R,3aS,6aR)-hexahydrofuro[2,3-b]-3-ol
于一100ml三口瓶中加入3.68gC1化合物·二苄胺盐和30ml四氢呋喃,冷却至0℃~5℃,缓慢滴加0.9g三光气的四氢呋喃溶液,滴毕,保温3小时,后缓慢滴加红铝,滴毕,再保温5小时,加酸淬灭,乙酸乙酯提取,蒸干溶剂,即得到目标化合物。 Add 3.68 g of C1 compound · dibenzylamine salt and 30 ml of tetrahydrofuran to a 100 ml three-necked flask, cool to 0 ° C ~ 5 ° C, slowly add 0.9 g of triphosgene tetrahydrofuran solution, drip, heat for 3 hours, then slowly add red The aluminum was added dropwise, and further kept for 5 hours, acid-quenched, extracted with ethyl acetate, and evaporated to dryness to give the title compound.
实施例9:Example 9
式C1化合物制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的一锅反应按照实施例8制备。A one-pot reaction of the compound of formula C1 to prepare (3R,3aS,6aR)-hexahydrofuro[2,3-b]-3-ol was prepared as in Example 8.
实施例10:式D-1化合物的制备Example 10: Preparation of a compound of formula D-1
于一100ml三口瓶中加入3.68gC1化合物·二苄胺盐和30ml四氢呋喃,冷却至0℃~5℃,缓慢滴加0.9g三光气的四氢呋喃溶液,滴毕,保温3小时,蒸干溶剂,核磁检测得到D-1化合物。 Add 3.68 g of C1 compound · dibenzylamine salt and 30 ml of tetrahydrofuran to a 100 ml three-necked flask, cool to 0 ° C ~ 5 ° C, slowly add 0.9 g of triphosgene tetrahydrofuran solution, drop, incubate for 3 hours, evaporate the solvent, NMR The D-1 compound was detected.

Claims (20)

  1. 一种具有如下通式B所示的化合物:A compound having the formula B below:
    Figure PCTCN2015089162-appb-100001
    Figure PCTCN2015089162-appb-100001
    其中,R1,R2为氢,相同或不同的为羧基保护基,所述羧基保护基为烷基,烷基硅基或取代苯基;PG为氢或羟基保护基,所述羟基保护基为烷基,烷基硅基,芳基。Wherein R 1 , R 2 are hydrogen, the same or different is a carboxy protecting group, the carboxy protecting group is an alkyl group, an alkylsilyl group or a substituted phenyl group; PG is a hydrogen or a hydroxy protecting group, and the hydroxy protecting group It is an alkyl group, an alkyl silicon group, and an aryl group.
  2. 根据权利要求1所述的化合物,进一步的为绝对立体构型式B-1化合物及其异构体,或进一步的为相对立体构型式B化合物,The compound according to claim 1, further comprising an absolute stereo configuration of the compound of formula B-1 and an isomer thereof, or further a compound of formula B in a relative stereo configuration,
    Figure PCTCN2015089162-appb-100002
    Figure PCTCN2015089162-appb-100002
    其中,R1,R2,PG与权利要求1中定义相同。Wherein R 1 , R 2 and PG are the same as defined in claim 1.
  3. 根据权利要求2所述的化合物,更进一步的为其绝对立体构型式B-1化合物,The compound according to claim 2, further a compound of the formula B-1 in its absolute stereo configuration,
    Figure PCTCN2015089162-appb-100003
    Figure PCTCN2015089162-appb-100003
    其中,R1,R2,PG与权利要求1中定义相同。 Wherein R 1 , R 2 and PG are the same as defined in claim 1.
  4. 权利要求1,2或3所述的化合物,其中,R1,R2相同或不同地为氢,苄基,甲基,乙基,正丙基,异丙基或叔丁基;所述PG为氢,叔丁基,三甲基硅烷基,三乙基甲硅烷基,三正丁基甲硅烷基,叔丁基二甲基甲硅烷基,苯基,二苯甲基,苄基,呋喃基,噻吩基,吲哚基。The compound according to claim 1, 2 or 3, wherein R 1 and R 2 are the same or different hydrogen, benzyl, methyl, ethyl, n-propyl, isopropyl or t-butyl; Is hydrogen, tert-butyl, trimethylsilyl, triethylsilyl, tri-n-butylsilyl, tert-butyldimethylsilyl, phenyl, diphenylmethyl, benzyl, furyl, Thienyl, fluorenyl.
  5. 一种绝对立体构型式C化合物及其异构体,或进一步的为相对立体构型式C化合物,An absolute stereoconfiguration of a compound of formula C and an isomer thereof, or further a compound of formula C in a relative stereo configuration,
    Figure PCTCN2015089162-appb-100004
    Figure PCTCN2015089162-appb-100004
  6. 根据权利要求5所述的化合物,更进一步的为其绝对立体构型式C1所示化合物,The compound according to claim 5, further a compound of the formula C1 in its absolute stereo configuration,
    Figure PCTCN2015089162-appb-100005
    Figure PCTCN2015089162-appb-100005
  7. 一种具有如下通式D所示化合物,a compound having the formula D below,
    Figure PCTCN2015089162-appb-100006
    Figure PCTCN2015089162-appb-100006
  8. 根据权利要求7所述的化合物,进一步的为绝对立体构型式D-1化合物及其异构体,或进一步的为相对立体构型式D化合物, The compound according to claim 7, further comprising an absolute stereo configuration of the compound of formula D-1 and an isomer thereof, or further a compound of formula D in a relative stereo configuration,
    Figure PCTCN2015089162-appb-100007
    Figure PCTCN2015089162-appb-100007
  9. 根据权利要求8所述的化合物,更进一步地为其绝对立体构型为式D-1化合物,The compound according to claim 8, further having its absolute stereo configuration as a compound of formula D-1,
    Figure PCTCN2015089162-appb-100008
    Figure PCTCN2015089162-appb-100008
  10. 式B所示化合物的制备方法,其特征在于,由式A1化合物与式A2化合物反应制备得到,A process for the preparation of a compound of the formula B, which is prepared by reacting a compound of the formula A1 with a compound of the formula A2,
    Figure PCTCN2015089162-appb-100009
    Figure PCTCN2015089162-appb-100009
    其中,R1,R2,PG与权利要求1中定义相同,所述X为离去基团,所述离去基团为卤素原子,甲磺酰氧基、三氟甲磺酰氧基、对甲苯磺酰氧基、苯磺酰氧基。Wherein R 1 , R 2 , PG are the same as defined in claim 1, wherein X is a leaving group, the leaving group is a halogen atom, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, P-toluenesulfonyloxy, benzenesulfonyloxy.
  11. 根据权利要求10所述的制备方法,其特征在于,所述X为碘原子,R1,R2相同或不同地为甲基,乙基,异丙基,叔丁基,苄基;所述保护基为叔丁基,三甲基硅烷基,苄基,二苯甲基。The method according to claim 10, wherein X is an iodine atom, and R 1 and R 2 are the same or different, methyl, ethyl, isopropyl, t-butyl, benzyl; The protecting group is tert-butyl, trimethylsilyl, benzyl, diphenylmethyl.
  12. 式C化合物的制备方法,其特征在于,由式B化合物经任意顺序的脱保护基,环合和水解反应制备得到, Process for the preparation of a compound of formula C, which is prepared from a compound of formula B by deprotection, cyclization and hydrolysis in any order,
    Figure PCTCN2015089162-appb-100010
    Figure PCTCN2015089162-appb-100010
    所述R1,R2,PG与权利要求1中定义相同。The R 1 , R 2 , PG are the same as defined in claim 1.
  13. 式C化合物的制备方法,其特征在于,由式A1化合物与式A2化合物反应后,经任意顺序地脱保护,环合和水解的一锅反应制备得到,A process for the preparation of a compound of the formula C, which is prepared by reacting a compound of the formula A1 with a compound of the formula A2, optionally subjected to one-pot reaction of deprotection, cyclization and hydrolysis,
    Figure PCTCN2015089162-appb-100011
    Figure PCTCN2015089162-appb-100011
  14. 式C1化合物·有机胺盐的制备方法,其特征在于,由式C化合物经与有机胺反应,并经游离后制备得到,所述有机胺为为氮上有活性氢的伯胺或氮上没有活性氢的叔胺。A method for preparing a compound of the formula C1, an organic amine salt, which is prepared by reacting a compound of the formula C with an organic amine which is free of primary amine or nitrogen on the nitrogen having active hydrogen. A tertiary amine of active hydrogen.
  15. 式D-1化合物的制备方法,其特征在于,由式C1化合物或式C1化合物·有机胺盐选择性地在催化剂的条件下反应制备得到,A method for producing a compound of the formula D-1, which is prepared by selectively reacting a compound of the formula C1 or a compound of the formula C1 with an organic amine salt under the conditions of a catalyst,
    Figure PCTCN2015089162-appb-100012
    Figure PCTCN2015089162-appb-100012
  16. (3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的制备方法,其特征在于,由式D-1化合物经还原和环合反应制备得到,Process for preparing (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, which is prepared by reduction and cyclization of a compound of formula D-1,
    Figure PCTCN2015089162-appb-100013
    Figure PCTCN2015089162-appb-100013
  17. (3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇的制备方法,其特征在于,由式C1化合物·有机胺盐或式C1化合物经一锅反应制备(3R,3aS,6aR)-六氢呋喃并[2,3-b]-3-醇,Process for preparing (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, which is prepared by one-pot reaction of a compound of formula C1, an organic amine salt or a compound of formula C1 (3R , 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol,
    Figure PCTCN2015089162-appb-100014
    Figure PCTCN2015089162-appb-100014
  18. 根据权利要求14,15或17所述的方法,其特征在于,所述有机胺为二苄胺、苄胺、二环己胺、环己胺、苯胺、二乙胺、二异丙胺、(S)-苯乙胺,二异丙基乙胺或三乙胺。The method according to claim 14, 15 or 17, wherein the organic amine is dibenzylamine, benzylamine, dicyclohexylamine, cyclohexylamine, aniline, diethylamine, diisopropylamine, (S ) - phenethylamine, diisopropylethylamine or triethylamine.
  19. 根据权利要求10或13所述的制备方法,其特征在于,所述A1化合物与A2化合物的反应在碱的存在下进行,所述碱为烷基锂或如下结构的化合物,The production method according to claim 10 or 13, wherein the reaction of the A1 compound with the A2 compound is carried out in the presence of a base which is an alkyllithium or a compound having the following structure,
    Figure PCTCN2015089162-appb-100015
    Figure PCTCN2015089162-appb-100015
    其中,L1,L2为烷基,环烷基,硅取代烷基,M为金属原子,其中金属原子为锂,钾或钠。Wherein, L 1 , L 2 are an alkyl group, a cycloalkyl group, a silicon-substituted alkyl group, and M is a metal atom, wherein the metal atom is lithium, potassium or sodium.
  20. 根据权利要求12或13所述的制备方法,其特征在于,所述脱保护试剂为酸或钯炭,所述环合试剂为有机酸或无机酸;所述水解试剂为无机碱。 The preparation method according to claim 12 or 13, wherein the deprotecting agent is an acid or palladium carbon, the cyclizing agent is an organic acid or an inorganic acid; and the hydrolysis reagent is an inorganic base.
PCT/CN2015/089162 2015-09-08 2015-09-08 Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof WO2017041228A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2015/089162 WO2017041228A1 (en) 2015-09-08 2015-09-08 Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof
CN202010282019.5A CN111410607B (en) 2015-09-08 2016-08-24 Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same
CN201610726487.0A CN106496263B (en) 2015-09-08 2016-08-24 Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/089162 WO2017041228A1 (en) 2015-09-08 2015-09-08 Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof

Publications (1)

Publication Number Publication Date
WO2017041228A1 true WO2017041228A1 (en) 2017-03-16

Family

ID=58240501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/089162 WO2017041228A1 (en) 2015-09-08 2015-09-08 Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof

Country Status (2)

Country Link
CN (2) CN111410607B (en)
WO (1) WO2017041228A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110423228B (en) * 2016-02-05 2023-01-10 成都博腾药业有限公司 Method for preparing darunavir intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864813A (en) * 2012-12-18 2014-06-18 上海迪赛诺化学制药有限公司 Synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and enantiomer thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0212341B8 (en) * 2001-09-10 2021-05-25 Janssen R&D Ireland intermediate compounds of hiv protease inhibitors and process for preparing the same
CN1202100C (en) * 2001-12-14 2005-05-18 中国科学院成都有机化学研究所 Synthetic method for (S)-3-hydroxy-gamma-butyrolactone
JP2005533821A (en) * 2002-06-27 2005-11-10 スミスクライン ビーチャム コーポレーション Preparation of stereoisomers of (3α, 3α / β, 6α / β) hexahydrofuro [2,3-b] furan-3-ol
CN100537575C (en) * 2002-12-27 2009-09-09 住友化学株式会社 Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof
EP1589018A4 (en) * 2002-12-27 2007-03-14 Sumitomo Chemical Co Process for producing hexahydrofurofuranol derivative, intermediate thereof and process for producing the same
TWI383975B (en) * 2004-03-31 2013-02-01 Tibotec Pharm Ltd Methods for the preparation of (3r,3as,6ar) hexahydro-furo[2,3-b]furan-3-ol
AU2005266313B2 (en) * 2004-07-26 2011-08-25 Merck Serono Sa N-hydroxyamide derivatives and use thereof
CN100441573C (en) * 2006-07-20 2008-12-10 厦门大学 Synthesis of S-(3)-hydroxy tetrahydrofuran
EP2883858B1 (en) * 2012-08-09 2017-12-27 Sumitomo Chemical Company Limited Method for producing hexahydrofurofuranol derivative
CN103896886A (en) * 2012-12-31 2014-07-02 上海迪赛诺化学制药有限公司 Darunavir midbody as well as preparation method and application thereof
CN110423228B (en) * 2016-02-05 2023-01-10 成都博腾药业有限公司 Method for preparing darunavir intermediate
CN107344944B (en) * 2016-05-07 2021-03-05 成都博腾药业有限公司 Method for preparing darunavir intermediate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864813A (en) * 2012-12-18 2014-06-18 上海迪赛诺化学制药有限公司 Synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and enantiomer thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALO, F. ET AL.: "Total Synthesis of Citrafungin A", JOURNAL OF ORGANIC CHEMISTRY, vol. 73, no. 24, 12 August 2008 (2008-08-12), pages 9692 - 9697, XP055368253 *
GERHARD, W. E. ET AL.: "Substrate Activity of Structural Analogs of Isocitrate for Isocitrate Dehydrogenases from Bovine Heart", BIOCHEMISTRY, vol. 14, no. 12, 31 December 1975 (1975-12-31), pages 2581 - 2588, XP055368254 *
HERETSCH, P. ET AL.: "Syntheses with a Chiral Building Block from the Citric Acid Cycle: (2R,3S)-Isocitric Acid by Fermentation of Sunflower Oil", ANGEWANDTE CHEMIE , INTERNATIONAL EDITION, vol. 47, no. 10, 31 December 2008 (2008-12-31), pages 2958 - 2960 *
ZHOU, SHIQIANG ET AL.: "Total Synthesis of (-)-Goniomitine", ORGANIC LETTERS, vol. 16, no. 12, 2 June 2014 (2014-06-02), XP055368252 *

Also Published As

Publication number Publication date
CN111410607B (en) 2023-05-09
CN111410607A (en) 2020-07-14
CN106496263B (en) 2020-10-30
CN106496263A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
US8329905B2 (en) Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate
US9000195B2 (en) Process for obtaining olopatadine and intermediates
JP2013129659A (en) Process and intermediate for preparing integrase inhibitor
KR20180128404A (en) Naphthyridine as an integrin antagonist
CN114478690B (en) Preparation method of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane derivative
WO2018082441A1 (en) Preparation method for 4-methylenepiperidine or acid addition salt thereof
JP2003535077A (en) Method for producing indole derivative and intermediate of the method
WO2016161826A1 (en) Method for preparing 4-isopropylamino-1-butanol
WO2017041228A1 (en) Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof
KR101810515B1 (en) 4-benzyl-1-phenethyl-piperazine-2,6-dione preparation method, and intermediate and preparation method thereof
US20080194825A1 (en) Process for obtaining montelukast
KR100990046B1 (en) New 4-halobenzylamine salts of montelukast and process for preparing montelukast sodium by using them
CA2491464A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
JP2010533208A (en) Method for producing tertiary alcohol
US10562834B2 (en) Process for preparing substituted crotonic acids
CN101891731A (en) Method for synthesizing olopatatadine E-configurational isomer
CN108727323B (en) Method for catalytically synthesizing trifluoromethyl substituted homoisoflavone compound by using N-heterocyclic carbene
WO2020125581A1 (en) Amide derivatives and preparation method for intermediates thereof
JP5448572B2 (en) Acetyl compound, method for producing the acetyl compound, and method for producing a naphthol compound using the acetyl compound
CN103073525A (en) Method for synthesizing (S)-(3,4-difluorophenyl)hexamethylene oxide
EP2880008B1 (en) Process for preparing spiro[2.5]octane-5,7-dione
JP4061333B2 (en) 2- (Pyrazol-1-yl) pyridine derivatives
US10836751B2 (en) Methods for preparing Nintedanib and intermediates thereof
CA2754802A1 (en) Process for the preparation of ramelteon
US9708284B2 (en) Process for the preparation of olopatadine and sylil intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15903335

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15903335

Country of ref document: EP

Kind code of ref document: A1